Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 30, 2007

Nobilon Acquires Rights from Vivalis to Advance its Flu Vaccine Initiative

  • Nobilon acquired rights from Vivalis to its EBx® cell lines and related technology platform. The cell lines, which are derived from avian embryonic stem cells, along with the technology, will be used to develop, produce, and market human influenza vaccines, including seasonal and pandemic.

    This worldwide, nonexclusive license deal includes an upfront payment, milestones, and royalties.

    “All human influenza vaccines currently available on the market are produced on chicken eggs,” notes Han van den Bosch, director R&D at Nobilon. “Nobilon already utilizes modern cell culture production, which has major advantages over egg production. We have several vaccines produced on mammalian cells in various stages of development. The Vivalis EBx avian cell line provides us with additional means for influenza vaccine production in the near future.”

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.